Effect of ABCG2 genotype on the oral bioavailability of topotecan

Cancer Biology and Therapy

Volumn 4, Issue 6, 2005, Pages

  Sparreboom, Alex ^a,b   Loos, Walter J ^b,d   Burger, Herman ^b   Sissung, Tristan M ^a   Verweij, Jaap ^b   Figg, William D ^a   Nooter, Kees ^b   Gelderblom, Hans ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABCG2; Accumulation; In vitro; Mutant; Pharmacogenetics; Pharmacokinetics; Topotecan

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; TOPOTECAN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG TRANSPORT; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC DIFFERENCE; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; MALE; OVARY CANCER; PILOT STUDY; WILD TYPE;

EID: 25144462079     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
2. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49.
3. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Rojo T, Bates SE. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938-46.
4. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6:71-84.
5. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004; 76:38-44.
6. Mizuarai S, Aozasa N, Kotani H. Single Nucleotide polymorphisms result in impaired membrane lacolization and reduced ATPase activity in multidrug transporter AMCG2. Int J Cancer 2004; 109:238-46.
7. Loos WJ, Stoter G, Verweij J, Schellens JH. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J Chromatogr B Biomed Appl 1996; 678:309-15.
8. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002; 1:096-702.
9. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 2003; 9:827-36.
10. Morisaki K, Robey RW, Nadjem T, Ozvegy CL, Honjo Y, Huff L, Sparreboom A, Sarkedi B, Bates Se. The Q141K single-nucleotide polymorphism impacts the transporter activity of ABCG2 [abstract]. Proc Am Assoc Cancer Res 2004; 45:2463.
11. Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH. Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 1998; 77:1645-52.
12. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Berweij J. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 1996; 73:1268-71.
13. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004; 10:5889-94.
14. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity. Oncologist 2004; 9:33-42.
15. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31:85-102.
16. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51:6039-44.
17. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92:1651-6.
18. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-64.
19. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosck T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99:15649-54.
20. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999; 146:117-26.
21. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20:2943-50.
22. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationskip to BCRP expression in human intestine. Pharmacogenetics 2003; 13:19-28.
23. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1:611-6.